Cel-Sci Corporation

CVM Healthcare Biotechnology

EPS
+65.4%
Free cash flow
−2.33%
Total debt
−39.7%

Quarter to June 2026, against a year earlier

1.45 0.08 +5.84%
Market cap
$24.1M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.63
Beneish M
−2.35
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.26 1.39 0.60 1.48
Net Debt/EBITDA
1.04 0.27 (0.58) 0.59
Debt/Equity
0.36 0.45 0.64 0.35
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.15) (0.50) (0.49) (0.33)
Book value per Share
3.93 1.39 0.84 0.90
Free Cash Flow
(4.68) (4.02) (4.02) (4.03)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026